冠心病治疗中瑞舒伐他汀和阿托伐他汀对TC、TG、HDL-C的影响探讨(1)
【摘要】 目的 探討冠心病患者采取瑞舒伐他汀和阿托伐他汀对TC、TG、HDL-C的影响。方法 60例冠心病患者， 随机分为观察组与对照组， 各30例。观察组采用瑞舒伐他汀钙片治疗， 对照组采用阿托伐他汀钙片治疗。观察比较两组患者临床效果、不良反应发生率、成本效果及总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)水平。结果 观察组TC(4.24±1.02)mmol/L、TG(1.44±0.57)mmol/L、HDL-C(1.45±0.31)mmol/L， 对照组分别为(4.32±1.08)、(1.45±0.42)、(1.41±0.27)mmol/L;两组TC、TG、HDL-C水平对比， 差异无统计学意义(P>0.05)。两组治疗总有效率及不良反应发生率对比， 差异无统计学意义(P>0.05)。阿托伐他汀钙片的成本效果比为67.78， 瑞舒伐他汀钙片的成本效果比为58.93;瑞舒伐他汀钙片的成本效果比低于阿托伐他汀钙片。结论 冠心病患者采取瑞舒伐他汀钙片和阿托伐他汀钙片治疗均具有显著的效果， 且可降低TC、TG水平， 提高HDL-C水平， 且具有一定的安全性， 但瑞舒伐他汀钙片的成本效果比较低， 值得在医院中推广并执行。
【关键词】 冠心病;瑞舒伐他汀;阿托伐他汀;总胆固醇;甘油三酯;高密度脂蛋白胆固醇
DOI：10.14163/j.cnki.11-5547/r.2020.26.004
【Abstract】 Objective To discuss the effect of rosuvastatin and atorvastatin on TC， TG and HDL-C in coronary heart disease. Methods A total of 60 cases of coronary heart disease patients were randomly divided into observation group and control group， with 30 cases in each group. The observation group was treated with rosuvastatin calcium tablets， and the control group was treated with atorvastatin calcium tablets. The clinical effect， incidence of adverse reactions， cost-effectiveness and total cholesterol (TC)， triglyceride (TG)， high-density lipoprotein cholesterol (HDL-C) levels were observed and compared between the two groups. Results TC， TG and HDL-C of the observation group was (4.24±1.02) mmol/L， (1.44±0.57) mmol/L and (1.45±0.31) mmol/L respectively， which was (4.32±1.08)， (1.45±0.42) and (1.41±0.27) mmol/L of the control group. There was no statistically significant difference in TC， TG and HDL-C between the two groups (P>0.05). There was no statistically significant difference in total effective rate of treatment and incidence of adverse reactions between the two groups (P>0.05). The cost-effectiveness ratio of atorvastatin calcium tablets was 67.78%， and the cost-effectiveness ratio of rosuvastatin calcium tablets was 58.93%; the cost-effectiveness ratio of rosuvastatin calcium tablets was lower than that of atorvastatin calcium tablets. Conclusion Both rosuvastatin calcium tablets and atorvastatin calcium tablets have significant effect for patients with coronary heart disease， and can reduce the level of TC， TG， improve the level of HDL-C， and has a certain safety. But the cost-effectiveness ratio of rosuvastatin calcium tablets is lower. It is worth promoting and implementing in the hospital.
【Key words】 Coronary heart disease; Rosuvastatin; Atorvastatin; Total cholesterol; Triglyceride; High-density lipoprotein cholesterol, http://www.100md.com(郑金亮 王俊峰 鲁冠男)
【关键词】 冠心病;瑞舒伐他汀;阿托伐他汀;总胆固醇;甘油三酯;高密度脂蛋白胆固醇
DOI：10.14163/j.cnki.11-5547/r.2020.26.004
【Abstract】 Objective To discuss the effect of rosuvastatin and atorvastatin on TC， TG and HDL-C in coronary heart disease. Methods A total of 60 cases of coronary heart disease patients were randomly divided into observation group and control group， with 30 cases in each group. The observation group was treated with rosuvastatin calcium tablets， and the control group was treated with atorvastatin calcium tablets. The clinical effect， incidence of adverse reactions， cost-effectiveness and total cholesterol (TC)， triglyceride (TG)， high-density lipoprotein cholesterol (HDL-C) levels were observed and compared between the two groups. Results TC， TG and HDL-C of the observation group was (4.24±1.02) mmol/L， (1.44±0.57) mmol/L and (1.45±0.31) mmol/L respectively， which was (4.32±1.08)， (1.45±0.42) and (1.41±0.27) mmol/L of the control group. There was no statistically significant difference in TC， TG and HDL-C between the two groups (P>0.05). There was no statistically significant difference in total effective rate of treatment and incidence of adverse reactions between the two groups (P>0.05). The cost-effectiveness ratio of atorvastatin calcium tablets was 67.78%， and the cost-effectiveness ratio of rosuvastatin calcium tablets was 58.93%; the cost-effectiveness ratio of rosuvastatin calcium tablets was lower than that of atorvastatin calcium tablets. Conclusion Both rosuvastatin calcium tablets and atorvastatin calcium tablets have significant effect for patients with coronary heart disease， and can reduce the level of TC， TG， improve the level of HDL-C， and has a certain safety. But the cost-effectiveness ratio of rosuvastatin calcium tablets is lower. It is worth promoting and implementing in the hospital.
【Key words】 Coronary heart disease; Rosuvastatin; Atorvastatin; Total cholesterol; Triglyceride; High-density lipoprotein cholesterol, http://www.100md.com(郑金亮 王俊峰 鲁冠男)